[go: up one dir, main page]

WO2025147179A1 - Composition pour la prévention ou le traitement de maladies cutanées à l'aide d'une polythérapie comprenant un inhibiteur de tubuline - Google Patents

Composition pour la prévention ou le traitement de maladies cutanées à l'aide d'une polythérapie comprenant un inhibiteur de tubuline Download PDF

Info

Publication number
WO2025147179A1
WO2025147179A1 PCT/KR2025/000258 KR2025000258W WO2025147179A1 WO 2025147179 A1 WO2025147179 A1 WO 2025147179A1 KR 2025000258 W KR2025000258 W KR 2025000258W WO 2025147179 A1 WO2025147179 A1 WO 2025147179A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
group
tofacitinib
colchicine
fingolimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2025/000258
Other languages
English (en)
Korean (ko)
Inventor
황준성
김지은
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cuepeak Bio Co ltd
Original Assignee
Cuepeak Bio Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cuepeak Bio Co ltd filed Critical Cuepeak Bio Co ltd
Publication of WO2025147179A1 publication Critical patent/WO2025147179A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating skin diseases, comprising a tubulin inhibitor and a specific compound as active ingredients.
  • the present invention relates to a pharmaceutical composition for preventing or improving skin diseases, comprising a tubulin inhibitor and a specific compound as active ingredients.
  • the present invention relates to a cosmetic composition for skin moisturizing, whitening, wrinkle improvement, acne relief, skin barrier strengthening, or skin keratinocyte differentiation, comprising a tubulin inhibitor and a specific compound as active ingredients.
  • Filaggrin The primary function of the skin is to act as a barrier separating the internal environment from the external environment, protecting against aggression by foreign substances and minimizing the loss of water and other essential body components to the external space.
  • Filaggrin is particularly important in the formation of the skin barrier because of its fundamental role in the final differentiation of the epidermis and its association with skin diseases. Filaggrin was first identified as an important structural protein in 1977 and was named filaggrin (filament-aggregating protein) when it was discovered that filaggrin acts to aggregate and compact keratin intermediate filaments. This protein is synthesized from the large precursor protein profilaggrin, which is the main component of keratin granules in the granular layer of the epidermis.
  • stratum corneum The main component of the skin barrier is the stratum corneum. This stratum corneum is the result of differentiation of keratinocytes as they migrate from the basal layer to the granulosum layer. As these cells mature, they express various structural proteins.
  • Filaggrin is continuously processed by various proteases. This proteolytic process releases hygroscopic amino acids and their derivatives, which form the natural moisturizing factor (NMF) that acts to retain moisture in the stratum corneum.
  • NMF moisturizing factor
  • filaggrin is converted from the precursor protein profilaggrin to active filaggrin monomer, and forms the stratum corneum by coagulating and compressing keratin filaments to flatten keratinocytes, and the natural moisturizing factor (NMF) generated during the filaggrin processing contributes to maintaining moisture in the skin and controlling acidic pH.
  • NMF moisturizing factor
  • filaggrin binds intermediate keratin filaments to structural proteins of the CE (keratinized epithelium), which gives keratinocytes strong mechanical and chemical resistance. Together with lipids released from lamellar bodies, filaggrin also contributes to the formation of the extracellular lipid matrix of the stratum corneum.
  • UCA Urocanic acid
  • PCA Pyrroliodone-5-carboxylic acid
  • UCA plays an important role in antimicrobial action and immune regulation.
  • a tubulin inhibitor when combined with a specific compound, increases the expression of filaggrin in epidermal cells, suppresses inflammatory signals, suppresses photoaging, suppresses collagen decomposition mechanisms, and exhibits a whitening effect, thereby completing the present invention.
  • the purpose of the present invention is to provide a pharmaceutical composition or a quasi-drug composition for preventing or treating skin diseases.
  • the purpose of the present invention is to provide a cosmetic composition for preventing or improving skin diseases and a cosmetic composition for moisturizing, whitening, improving wrinkles, alleviating acne, strengthening the skin barrier, or differentiating skin keratinocytes.
  • the present invention provides a pharmaceutical composition for preventing or treating skin diseases, comprising as an active ingredient a tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof.
  • the present invention provides a pharmaceutical composition containing the effective ingredient for preventing, improving or treating a skin disease, a cosmetic composition for preventing or improving a skin disease, and a cosmetic composition for moisturizing, whitening, improving wrinkles, alleviating acne, strengthening the skin barrier or differentiating skin keratinocytes.
  • the present invention provides a method for preventing or treating a skin disease, comprising the step of administering to a subject in need thereof a tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof.
  • tubulin inhibitor of the present invention increases the expression level of filaggrin in epidermal cells, promotes skin differentiation, inhibits the NF-kB signaling process induced by TNF- ⁇ , exhibits photoaging inhibition and wrinkle improvement effects, and exhibits a synergistic effect in whitening effect.
  • this combination therapy can be utilized as an effective ingredient that simultaneously exhibits activities such as skin moisturizing, whitening, wrinkle improvement, acne relief, skin barrier strengthening, or skin keratinocyte differentiation, in addition to prevention, treatment, or improvement of skin diseases.
  • combination in the present invention refers to the use of combined administration of one or more compounds selected from the group consisting of a tubulin inhibitor and calcium, colchicine, tapinarof, fingolimod, tofacitinib, or a pharmaceutically acceptable salt thereof, and can be understood to have the same meaning as “combined use.”
  • tubulin inhibitors and one or more compounds selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof may be co-administered.
  • tubulin inhibitor i) tubulin inhibitor; and, at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof; co-administered using a pharmaceutical composition comprising the same in the form of a mixture or in separate, separate forms;
  • the method may be a combination of administering a pharmaceutical composition comprising a tubulin inhibitor and a pharmaceutical composition comprising at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof, simultaneously, sequentially, or in reverse order, but is not limited thereto.
  • composition may be administered in a separate form, including, but not limited to, one or more compounds selected from the group consisting of a tubulin inhibitor and calcium, colchicine, tapinarof, fingolimod, tofacitinib, or a pharmaceutically acceptable salt thereof.
  • one or more compounds selected from the group consisting of a tubulin inhibitor and calcium, colchicine, tapinarof, fingolimod, tofacitinib, or a pharmaceutically acceptable salt thereof may be formulated together in a separate, separate form; or they may be formulated as separate formulations so that the separate formulations can be administered simultaneously, separately, sequentially, or in reverse order.
  • “combined administration”, “combined use”, or “combining” should be understood not only as simultaneous administration, but also as an administration form in which one or more compounds selected from the group consisting of a tubulin inhibitor; and calcium, colchicine, tapinarof, fingolimod, tofacitinib, or a pharmaceutically acceptable salt thereof act together in a subject so that each substance can perform a level equivalent to or higher than its original function. Therefore, when the term “combined use” is used herein, it should be understood that it refers to simultaneous, separate, sequential, or reverse administration, and that the order is unlimited. When the administration is sequential, reverse, or separate, the order of administration is not particularly limited, but the interval between the administration of two or more components should be such that the beneficial effect of the combination is not lost.
  • the preferred dosage of the pharmaceutical composition and the combined component according to the present invention varies depending on the patient's condition, weight, degree of disease, drug form, administration route, and period, but can be appropriately selected by those skilled in the art. However, in order to achieve a preferred effect, it can be administered at 0.0001 to 500 mg/kg per day, specifically 0.001 to 500 mg/kg. The administration can be done once a day or divided into several times. However, the scope of the present invention is not limited by the above dosage.
  • a composition comprising a combination according to the present invention is for co-administering a tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof, wherein the G tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof may be formulated into a single formulation.
  • kit refers to a combination comprising a tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof, for co-administration with a tubulin inhibitor; and may include a combination or composition according to the present invention for co-administration with a tubulin inhibitor.
  • the kit according to the present invention comprises: a) a tubulin inhibitor formulated as a single formulation and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof; b) a tubulin inhibitor; And one or more compounds selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, or pharmaceutically acceptable salts thereof; each of which may be included as an individual formulation, and may additionally include a substance necessary for combined administration of two or more substances, but is not limited thereto.
  • the present invention provides a combination therapy in which, when a tubulin inhibitor and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof are used in combination, a synergistic effect is exhibited in increasing filaggrin expression in cells, inhibiting photoaging, inhibiting inflammatory signaling mechanisms, differentiating skin cells, and whitening.
  • skin disease is a group of diseases caused by structural and functional abnormalities of the skin, and is a concept encompassing abnormal conditions occurring in the skin that can be caused by various causes such as inflammation, infection, allergy, and immune abnormality.
  • the skin disease may be at least one selected from the group consisting of, for example, atopic dermatitis, skin thermal damage, pruritus, acne, psoriasis, allergic dermatitis, contact dermatitis, exfoliative dermatitis, seborrheic dermatitis, seborrheic dermatitis, lichen planus, rosacea, pigmentation disorders, hypermelanosis, erythema, wounds, ulcers, bedsores, lupus, skin wrinkle-related diseases, and skin diseases caused by photodamage, without limitation in type.
  • atopic dermatitis skin thermal damage, pruritus, acne, psoriasis, allergic dermatitis, contact dermatitis, exfoliative dermatitis, seborrheic dermatitis, seborrheic dermatitis, lichen planus, rosacea, pigmentation disorders, hypermelanosis, erythema, wounds, ulcers, bedsores, lupus,
  • the above skin wrinkle-related diseases may be elasticity fibrosis, thinning of the skin, skin atrophy, decrease in collagen fibers and elastic fibers, loss of skin elasticity, dryness, wrinkle formation, or premature skin aging.
  • the skin diseases caused by the photodamage may be lentigines, freckles, hypopigmentation, hyperpigmentation, photodamage due to acute or chronic UV radiation, or photosensitivity.
  • the skin disease of the present invention may be squamous cell carcinoma, basal cell carcinoma, benign epithelial tumor, and radiation dermatitis.
  • the pharmaceutical composition may comprise a pharmaceutically effective amount of the tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof.
  • the above pharmaceutical composition may be formulated as an oral or parenteral dosage form.
  • the oral dosage form may be a granule, powder, solution, tablet, capsule, dry syrup, or a combination thereof.
  • the parenteral dosage form may be an injection, ointment, aerosol, spray, patch, etc., and the dosage form is not limited.
  • the dosage of the pharmaceutical composition according to one example is, for example, about 0.0001 to 10,000 mg/kg, 0.0001 to 5,000 mg/kg, 0.0001 to 1,000 mg/kg, 0.0001 to 900 mg/kg, 0.0001 to 800 mg/kg, 0.0001 to 700 mg/kg, 0.0001 to 600 mg/kg, 0.0001 to 500 mg/kg, 0.0001 to 400 mg/kg, 0.0001 to 300 mg/kg, 0.0001 to 200 mg/kg, 1 to 1,000 mg/kg, 1 to 900 mg/kg, 1 to 800 mg/kg, 1 to 700 mg/kg, 1 to 600 mg/kg, 1 to 500 mg/kg, 1 to 450 mg/kg, 1 to 400 mg/kg, 1 to 350 mg/kg, 1 to 300 mg/kg, 1 to 250 mg/kg, 10 to 1000 mg/kg, 10 to 900 mg/kg, 10 to 800 mg/kg, 10 to 700 mg/kg, 10 to 600 mg/kg, 10 to 500 mg/kg, 10 to 450 mg/kg, 10 to 400 mg/kg,
  • quasi-drugs refer to all products other than drugs related to the treatment or prevention of diseases.
  • the quasi-drugs above refer to products that are used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases of humans or animals, and have a milder effect than drugs.
  • quasi-drugs are products other than those used for the purpose of drugs, and may include, but are not limited to, fiber and rubber products used for the treatment or prevention of diseases of humans or animals, non-applied or non-direct effects on the human body, non-applied instruments or machines and similar thereto, sterilizers and insecticides for preventing infectious diseases, etc.
  • the type or formulation of the pharmaceutical composition of the present invention is not particularly limited, but may preferably be a disinfectant, a shower foam, a garglin, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment, or a filter filler.
  • the composition of the present invention when included in an quasi-drug for skin moisturizing purposes, the composition can be used as is or together with other quasi-drug ingredients, and can be used appropriately according to a conventional method.
  • the mixing amount of the effective ingredients can be appropriately determined depending on the intended use, and the quasi-drug composition according to the present invention can contain 0.01 to 20 wt% of the tubulin inhibitor; and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, or pharmaceutically acceptable salts thereof, based on the total weight of the composition.
  • the present invention provides a cosmetic composition for preventing or improving skin diseases, comprising as an active ingredient at least one compound selected from the group consisting of a tubulin inhibitor; and calcium, colchicine, tapinarof, fingolimod, tofacitinib, or a pharmaceutically acceptable salt thereof.
  • improvement herein may mean any action that at least reduces the severity of a symptom, for example, a parameter associated with alleviating or curing a condition.
  • the above cosmetic composition is not particularly limited to a specific formulation, and the formulation can be appropriately selected depending on the purpose.
  • the above cosmetic composition may have, for example, a solubilized formulation, an emulsified formulation, or a dispersed formulation.
  • the above cosmetic composition may have a cosmetic formulation of a flexible toner, a nourishing toner, a massage cream, a nourishing cream, an essence, a pack, a gel, an ampoule, or a skin adhesive type, but is not limited thereto.
  • the above cosmetic composition may additionally contain ingredients commonly used in cosmetic compositions in addition to the effective ingredients disclosed herein, and may include, for example, conventional auxiliary agents and carriers such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, preservatives, vitamins, pigments, and fragrances.
  • conventional auxiliary agents and carriers such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, preservatives, vitamins, pigments, and fragrances.
  • the term “strengthening the skin barrier” may mean any action that enhances the function of the skin barrier, which is located at the outermost part of the skin and prevents moisture and nutrient loss.
  • Administration may be by a method known in the art.
  • the administration method such as the route of administration and the number of administrations, may be appropriately selected by a person skilled in the art.
  • Administration may be directly administered to a subject by any means, for example, intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intrabuccal, intratracheal or subcutaneous administration.
  • the administration may be systemic or local.
  • the administration may include application to the skin.
  • administration is 0.1 mg to 1,000 mg per day per individual of the composition according to one specific example, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg
  • the dosage may be administered in an amount of 100 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg.
  • the dosage may be prescribed in various ways depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and response sensitivity, and a person skilled in the art can appropriately adjust the dosage considering these factors.
  • the number of administrations may be once a day or twice or more within the range of clinically acceptable side effects, and the administration may be administered to one or more sites, and the total number of administration days may be from 1 to 30 days for one treatment at intervals of 2 to 5 days daily. If necessary, the same treatment may be repeated after an appropriate period.
  • the same dosage per kg as for humans may be administered, or the dosage may be converted into the above dosage based on, for example, the volume ratio of organs (such as the heart) between the target animal and the human (e.g., average value).
  • tubulin inhibitor and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof, for use in preparing a composition for preventing, ameliorating or treating a skin disease.
  • tubulin inhibitor and at least one compound selected from the group consisting of calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof, for use in the manufacture of a medicament for preventing, ameliorating or treating a skin disease.
  • Another aspect provides a food composition for preventing or improving skin diseases, comprising as an active ingredient at least one compound selected from the group consisting of a tubulin inhibitor; and calcium, colchicine, tapinarof, fingolimod, tofacitinib, and pharmaceutically acceptable salts thereof.
  • the food composition may include a health functional food.
  • the food composition according to one embodiment of the present invention may be in a liquid or solid form, and may be in the form of a tablet, capsule, soft capsule, pill, granule, beverage (drink), diet bar, chocolate, caramel or confectionery, and the form is not particularly limited.
  • the food composition of the present invention may contain excipients, sugars, flavorings, colorings, fats, proteins, etc. as needed.
  • the decreasing absorbance value at this time was measured at 490 nm to evaluate the degree of tyrosinase inhibition.
  • ABT-751 or TN16 was treated at a concentration of 1.0 ⁇ M to 2 mM of L-tyrosine, the substrate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

La présente divulgation concerne une composition pharmaceutique, une composition quasi-médicamenteuse ou une composition cosmétique comprenant : un inhibiteur de tubuline ; et au moins un composé sélectionné dans le groupe constitué par le calcium, la colchicine, le tapinarof, le fingolimod, le tofacitinib et des sels pharmaceutiquement acceptables associés en tant que principes actifs pour la prévention, le soulagement ou le traitement de maladies cutanées. La polythérapie de la présente invention peut être utilisée en tant que principe actif présentant simultanément des activités telles que l'hydratation de la peau, le blanchiment de la peau, l'atténuation des rides, l'atténuation de l'acné, le renforcement de la barrière cutanée ou la différenciation des kératinocytes cutanés, en plus de la prévention, du traitement ou du soulagement de maladies cutanées.
PCT/KR2025/000258 2024-01-05 2025-01-06 Composition pour la prévention ou le traitement de maladies cutanées à l'aide d'une polythérapie comprenant un inhibiteur de tubuline Pending WO2025147179A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20240001893 2024-01-05
KR10-2024-0001893 2024-01-05

Publications (1)

Publication Number Publication Date
WO2025147179A1 true WO2025147179A1 (fr) 2025-07-10

Family

ID=96300601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2025/000258 Pending WO2025147179A1 (fr) 2024-01-05 2025-01-06 Composition pour la prévention ou le traitement de maladies cutanées à l'aide d'une polythérapie comprenant un inhibiteur de tubuline

Country Status (2)

Country Link
KR (2) KR20250108066A (fr)
WO (1) WO2025147179A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644008B1 (fr) * 2003-05-29 2011-12-21 Abbott Laboratories Schema posologique d'administration en continu
WO2019173533A1 (fr) * 2018-03-07 2019-09-12 Athenex HK Innovative Limited Compositions et méthodes de traitement des troubles cutanés hyperprolifératifs
KR20210093174A (ko) * 2020-01-17 2021-07-27 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
KR20220041125A (ko) * 2019-07-24 2022-03-31 솔-겔 테크놀로지스 리미티드 국부 타피나로프-egfr 억제제 조성물을 이용한 피부 장애의 치료

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644008B1 (fr) * 2003-05-29 2011-12-21 Abbott Laboratories Schema posologique d'administration en continu
WO2019173533A1 (fr) * 2018-03-07 2019-09-12 Athenex HK Innovative Limited Compositions et méthodes de traitement des troubles cutanés hyperprolifératifs
KR20220041125A (ko) * 2019-07-24 2022-03-31 솔-겔 테크놀로지스 리미티드 국부 타피나로프-egfr 억제제 조성물을 이용한 피부 장애의 치료
KR20210093174A (ko) * 2020-01-17 2021-07-27 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HONG JIN-BON, WU PO-YUAN, QIN ALBERT, HUANG YI-WEN, TSENG KUAN-CHIAO, LAI CHING-YU, CHAN WING-KAI, FANG JANE, CUTLER DAVID L., TSA: "Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results", PHARMACEUTICS, vol. 14, no. 10, 1 January 2022 (2022-01-01), Switzerland, pages 1 - 12, XP093334385, ISSN: 1999-4923, DOI: 10.3390/pharmaceutics14102159 *

Also Published As

Publication number Publication date
KR20250108066A (ko) 2025-07-15
KR20250114272A (ko) 2025-07-29

Similar Documents

Publication Publication Date Title
KR101081914B1 (ko) 생약혼합물로부터 추출한 추출물을 함유하는 피부 외용제 조성물
KR101081913B1 (ko) 발효 생약추출물을 함유하는 피부 외용제 조성물
US20120128784A1 (en) Composition containing bee venom as an active ingredient for preventing and treating acne
KR101900065B1 (ko) 프로텍틴 dx를 유효성분으로 포함하는 피부 노화 예방 또는 치료용 조성물 및 그의 용도
CZ301019B6 (cs) Vitamín E a jeho estery pro použití pri lokální lécbe onemocnení vaginální sliznice
WO2019027132A1 (fr) Composition pour prévention ou traitement des cicatrices
KR101186130B1 (ko) 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물
KR101863297B1 (ko) 클로로겐산 및 루틴 화합물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물
JP2007182444A (ja) ハッカの抽出物の化粧的使用
WO2021145699A1 (fr) Composition pour le traitement de maladies de la peau, comprenant de la colchicine
KR101900066B1 (ko) 마레신 1을 유효성분으로 포함하는 피부 노화 예방 또는 치료용 조성물 및 그의 용도
KR101458496B1 (ko) 아위버섯 자실체 추출물 또는 아위버섯 균사체 추출물 또는 아위버섯 균사체 배양액을 함유하는 항염용 피부 외용제 조성물
WO2025147179A1 (fr) Composition pour la prévention ou le traitement de maladies cutanées à l'aide d'une polythérapie comprenant un inhibiteur de tubuline
EP3329905A1 (fr) Compositions cosmötiques topiques contenant d'un oligpeptide contre le vieillisement de la peau
WO2025147178A1 (fr) Composition comprenant un inhibiteur de tubuline pour prévenir ou traiter des maladies cutanées
KR101208013B1 (ko) 참바늘버섯 균사체 추출물을 함유하는 피부 외용제 조성물
KR20140081137A (ko) 곰보버섯 자실체 추출물 또는 곰보버섯 균사체 추출물을 함유하는 피부 외용제 조성물
WO2025147180A1 (fr) Composition comprenant un inhibiteur de tubuline pour prévenir ou traiter des maladies cutanées
WO2017146341A1 (fr) Composition pour le traitement des plaies, contenant de la daphnine, et son utilisation
KR102751617B1 (ko) 이소클로로겐산 또는 이의 염을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물
KR101769545B1 (ko) 다프닌을 포함하는 상처 치료용 조성물 및 그의 용도
KR101460672B1 (ko) 참바늘버섯 자실체 추출물을 함유하는 모발손상 방지용 조성물
KR101305411B1 (ko) 참바늘버섯 균사체 추출물을 함유하는 피부 외용제 조성물
WO2025147181A1 (fr) Composition pour la prévention ou le traitement de la chute de cheveux comprenant un inhibiteur de tubuline
WO2025198324A1 (fr) Nanomicelles à auto-assemblage de polymère ciblé sur des cellules, et leur procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25736332

Country of ref document: EP

Kind code of ref document: A1